almagate has been researched along with Retrolental Fibroplasia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chandra, P; Sankar, J; Sankar, MJ | 1 |
| Cataltepe, SU; VanderVeen, DK | 1 |
| Bhat, V; Mehta, M; Sankar, J; Sankar, MJ; Srinivasan, R | 1 |
| Autrata, R; Borek, I; Dolezel, Z; Holousová, M; Krejcírová, I; Senková, K | 1 |
| Mintz-Hittner, HA | 1 |
| Joussen, AM | 1 |
4 review(s) available for almagate and Retrolental Fibroplasia
| Article | Year |
|---|---|
Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Combined Modality Therapy; Cryotherapy; Humans; Infant, Newborn; Intravitreal Injections; Laser Therapy; Randomized Controlled Trials as Topic; Ranibizumab; Retinal Detachment; Retinopathy of Prematurity; Vascular Endothelial Growth Factor A | 2018 |
Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Infant, Newborn; Infant, Premature; Intravitreal Injections; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinopathy of Prematurity; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Combined Modality Therapy; Cryotherapy; Humans; Infant, Newborn; Intravitreal Injections; Laser Therapy; Randomized Controlled Trials as Topic; Retinal Detachment; Retinopathy of Prematurity; Vascular Endothelial Growth Factor A | 2016 |
[Molecular pathogenesis of ocular vascular disease--anti-angiogenesis as a therapeutic concept].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Angiopathies; Diabetic Retinopathy; Humans; Infant, Newborn; Macular Degeneration; Neovascularization, Pathologic; Ranibizumab; Retinal Diseases; Retinopathy of Prematurity; Vascular Diseases | 2007 |
1 trial(s) available for almagate and Retrolental Fibroplasia
| Article | Year |
|---|---|
[Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Combined Modality Therapy; Humans; Infant; Infant, Newborn; Injections, Intraocular; Laser Coagulation; Retinopathy of Prematurity; Vascular Endothelial Growth Factor A | 2012 |
1 other study(ies) available for almagate and Retrolental Fibroplasia
| Article | Year |
|---|---|
Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors.
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Infant; Infant, Newborn; Infant, Premature; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinopathy of Prematurity; Vascular Endothelial Growth Factors | 2012 |